FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021021623> ?p ?o ?g. }

• W2021021623 endingPage "1236" @default.
• W2021021623 startingPage "1228" @default.
• W2021021623 abstract "Purpose: Clusterin plays important roles in cell survival and death. Inactivation of clusterin enhances the therapeutic efficacy of chemotherapy in lung cancer models. The purpose of this study was to determine whether inhibition of clusterin by an antisense-based investigative drug enhances radiation sensitization in a lung cancer model. Methods and Materials: Cells were transfected with an antisense oligonucleotide (ASO) against clusterin (OGX-011). Apoptosis was determined by 7-aminoactinomycin D staining. Cell survival was examined by 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) and clonogenic assay. Xenograft model was used to demonstrate tumor growth and tumor blood flow. Results: OGX-011 specifically attenuated the expression of secreted clusterin (prosurvival), with no apparent effect on the expression of nuclear clusterin (proapoptotic). Apoptosis was significantly increased when H460 lung cancer cells were treated with OGX-011 plus radiation. Inhibition of clusterin followed by radiation greatly decreased cell survival. H460 xenografts that were treated with OGX-011 plus radiotherapy demonstrated growth delay beyond 17 days. Doppler studies showed that tumor blood flow was compromised when mice bearing H460 xenografts were treated with OGX-011 and radiation. Conclusion: A combination of radiotherapy and OGX-011 improved control of tumor growth and vascular regression in the H460 lung cancer model. Purpose: Clusterin plays important roles in cell survival and death. Inactivation of clusterin enhances the therapeutic efficacy of chemotherapy in lung cancer models. The purpose of this study was to determine whether inhibition of clusterin by an antisense-based investigative drug enhances radiation sensitization in a lung cancer model. Methods and Materials: Cells were transfected with an antisense oligonucleotide (ASO) against clusterin (OGX-011). Apoptosis was determined by 7-aminoactinomycin D staining. Cell survival was examined by 3-(4, 5-methylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) and clonogenic assay. Xenograft model was used to demonstrate tumor growth and tumor blood flow. Results: OGX-011 specifically attenuated the expression of secreted clusterin (prosurvival), with no apparent effect on the expression of nuclear clusterin (proapoptotic). Apoptosis was significantly increased when H460 lung cancer cells were treated with OGX-011 plus radiation. Inhibition of clusterin followed by radiation greatly decreased cell survival. H460 xenografts that were treated with OGX-011 plus radiotherapy demonstrated growth delay beyond 17 days. Doppler studies showed that tumor blood flow was compromised when mice bearing H460 xenografts were treated with OGX-011 and radiation. Conclusion: A combination of radiotherapy and OGX-011 improved control of tumor growth and vascular regression in the H460 lung cancer model." @default.
• W2021021623 created "2016-06-24" @default.
• W2021021623 creator A5003632538 @default.
• W2021021623 creator A5007306614 @default.
• W2021021623 creator A5039512947 @default.
• W2021021623 creator A5044220823 @default.
• W2021021623 creator A5051475333 @default.
• W2021021623 creator A5062125605 @default.
• W2021021623 creator A5073072491 @default.
• W2021021623 creator A5075232420 @default.
• W2021021623 creator A5086146759 @default.
• W2021021623 date "2005-11-01" @default.
• W2021021623 modified "2023-10-17" @default.
• W2021021623 title "Clusterin as a therapeutic target for radiation sensitization in a lung cancer model" @default.
• W2021021623 cites W1562188985 @default.
• W2021021623 cites W189012360 @default.
• W2021021623 cites W1964904520 @default.
• W2021021623 cites W1965837532 @default.
• W2021021623 cites W1970543525 @default.
• W2021021623 cites W1970862339 @default.
• W2021021623 cites W1971149805 @default.
• W2021021623 cites W1984896996 @default.
• W2021021623 cites W1986962731 @default.
• W2021021623 cites W1991441695 @default.
• W2021021623 cites W1994397710 @default.
• W2021021623 cites W1996945731 @default.
• W2021021623 cites W2003006566 @default.
• W2021021623 cites W2013242810 @default.
• W2021021623 cites W2014697599 @default.
• W2021021623 cites W2021316249 @default.
• W2021021623 cites W2024472073 @default.
• W2021021623 cites W2030889696 @default.
• W2021021623 cites W2031719598 @default.
• W2021021623 cites W2039901479 @default.
• W2021021623 cites W2049119567 @default.
• W2021021623 cites W2066246322 @default.
• W2021021623 cites W2075098575 @default.
• W2021021623 cites W2079138189 @default.
• W2021021623 cites W2090216358 @default.
• W2021021623 cites W2106567289 @default.
• W2021021623 cites W2109990295 @default.
• W2021021623 cites W2115173772 @default.
• W2021021623 cites W2117170342 @default.
• W2021021623 cites W2128599664 @default.
• W2021021623 cites W2151623120 @default.
• W2021021623 cites W2157255230 @default.
• W2021021623 cites W2165033740 @default.
• W2021021623 cites W2171011502 @default.
• W2021021623 cites W2183542972 @default.
• W2021021623 cites W2265903980 @default.
• W2021021623 cites W3026227968 @default.
• W2021021623 cites W4245265700 @default.
• W2021021623 doi "https://doi.org/10.1016/j.ijrobp.2005.07.956" @default.
• W2021021623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16253777" @default.
• W2021021623 hasPublicationYear "2005" @default.
• W2021021623 type Work @default.
• W2021021623 sameAs 2021021623 @default.
• W2021021623 citedByCount "29" @default.
• W2021021623 countsByYear W20210216232012 @default.
• W2021021623 countsByYear W20210216232013 @default.
• W2021021623 countsByYear W20210216232014 @default.
• W2021021623 countsByYear W20210216232015 @default.
• W2021021623 countsByYear W20210216232017 @default.
• W2021021623 countsByYear W20210216232018 @default.
• W2021021623 countsByYear W20210216232019 @default.
• W2021021623 countsByYear W20210216232021 @default.
• W2021021623 countsByYear W20210216232022 @default.
• W2021021623 crossrefType "journal-article" @default.
• W2021021623 hasAuthorship W2021021623A5003632538 @default.
• W2021021623 hasAuthorship W2021021623A5007306614 @default.
• W2021021623 hasAuthorship W2021021623A5039512947 @default.
• W2021021623 hasAuthorship W2021021623A5044220823 @default.
• W2021021623 hasAuthorship W2021021623A5051475333 @default.
• W2021021623 hasAuthorship W2021021623A5062125605 @default.
• W2021021623 hasAuthorship W2021021623A5073072491 @default.
• W2021021623 hasAuthorship W2021021623A5075232420 @default.
• W2021021623 hasAuthorship W2021021623A5086146759 @default.
• W2021021623 hasConcept C117262875 @default.
• W2021021623 hasConcept C121608353 @default.
• W2021021623 hasConcept C126322002 @default.
• W2021021623 hasConcept C142724271 @default.
• W2021021623 hasConcept C190283241 @default.
• W2021021623 hasConcept C203014093 @default.
• W2021021623 hasConcept C2776217527 @default.
• W2021021623 hasConcept C2776256026 @default.
• W2021021623 hasConcept C2779476363 @default.
• W2021021623 hasConcept C502942594 @default.
• W2021021623 hasConcept C509974204 @default.
• W2021021623 hasConcept C55493867 @default.
• W2021021623 hasConcept C71924100 @default.
• W2021021623 hasConcept C86803240 @default.
• W2021021623 hasConcept C96232424 @default.
• W2021021623 hasConceptScore W2021021623C117262875 @default.
• W2021021623 hasConceptScore W2021021623C121608353 @default.
• W2021021623 hasConceptScore W2021021623C126322002 @default.
• W2021021623 hasConceptScore W2021021623C142724271 @default.
• W2021021623 hasConceptScore W2021021623C190283241 @default.
• W2021021623 hasConceptScore W2021021623C203014093 @default.

• next